Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by TD Asset Management Inc

Key Points

• TD Asset Management Inc reduced its stake in Krystal Biotech, Inc. by 7.4%, now holding approximately 0.14% of the company valued at $7.26 million.
• Several institutional investors, including FMR LLC and Soleus Capital Management, have adjusted their holdings, with notable increases during the fourth quarter.
• Analysts generally view Krystal Biotech positively, with a consensus rating of "Buy" and a target price of $211.33, despite the company recently missing earnings estimates.

TD Asset Management Inc cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,268 shares of the company's stock after selling 3,212 shares during the quarter. TD Asset Management Inc owned 0.14% of Krystal Biotech worth $7,260,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. FMR LLC boosted its stake in shares of Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after buying an additional 21,133 shares during the period. Avoro Capital Advisors LLC increased its stake in shares of Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after buying an additional 6,600 shares during the period. Hood River Capital Management LLC raised its holdings in Krystal Biotech by 2.1% in the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after acquiring an additional 10,622 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after acquiring an additional 71,200 shares in the last quarter. Finally, Soleus Capital Management L.P. grew its holdings in Krystal Biotech by 65.2% during the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after acquiring an additional 141,400 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 2.0%

Shares of Krystal Biotech stock traded up $3.11 on Friday, hitting $156.98. The stock had a trading volume of 571,859 shares, compared to its average volume of 279,487. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84. The stock has a market cap of $4.54 billion, a price-to-earnings ratio of 37.74 and a beta of 0.70. The company's 50 day moving average price is $140.83 and its 200 day moving average price is $155.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. Analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares of the company's stock, valued at $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

KRYS has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Friday, July 25th. Chardan Capital reiterated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a report on Friday, July 25th. Bank of America decreased their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Citigroup reaffirmed a "neutral" rating and set a $176.00 price target (up from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Finally, Guggenheim decreased their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $211.33.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).